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ABSTRACT
The positive transcription elongation factor b
(P-TEFb) regulates RNA polymerase II elongation.
In cells, P-TEFb partitions between small active
and larger inactive states. In the latter, HEXIM1
binds to 7SK snRNA and recruits as well as inacti-
vates P-TEFb in the 7SK snRNP. Several stimuli can
affect this P-TEFb equilibrium. In this study, we
demonstrate that protein kinase C (PKC) phosphor-
ylates the serine at position158 (S158) in HEXIM1.
This phosphorylated HEXIM1 protein neither binds
to 7SK snRNA nor inhibits P-TEFb. Phorbol esters or
the engagement of the T cell antigen receptor,
which activate PKC and the expression of the con-
stitutively active (CA) PKCh protein, which is found
in T cells, inhibit the formation of the 7SK snRNP. All
these stimuli increase P-TEFb-dependent transcrip-
tion. In contrast, the kinase-negative PKCh and the
mutant HEXIM1 (S158A) proteins block effects of
these PKC-activating stimuli. These results
indicate that the phosphorylation of HEXIM1 by
PKC represents a major regulatory step of P-TEFb
activity in cells.
INTRODUCTION
Eukaryotic transcription by RNA polymerase II
(RNAPII) is regulated at multiple steps including initi-
ation, promoter clearance, elongation and cotranscrip-
tional processing of nascent transcripts (1). Recent
genome-wide analyses revealed that elongation is a
critical step of transcription (2–4). The positive transcrip-
tion elongation factor b (P-TEFb), which contains cyclins
T1 or T2 (CycT1, CycT2; collectively, CycT) and cyclin-
dependent kinase 9 (CDK9), plays a major stimulatory
role in this process. P-TEFb phosphorylates serines at
position 2 (S2) in the C-terminal domain (CTD) of
RNAPII as well as DRB (5,6-dichloro-1 -b-D-ribofurano-
sylbenzimidazole) sensitivity-inducing factor (DSIF) and
the negative elongation factor (NELF) (5). In cells,
P-TEFb exists in two major forms (5,6). The catalytically
active P-TEFb binds bromodomain containing protein
4 (BRD4), subunits of the super elongation complex
(SEC), or other DNA- or RNA-bound activators (7–10).
In contrast, the 7SK snRNP is inactive and contains
7SK snRNA, hexamethylene bisacetamide-(HMBA)-
induced mRNA-encoded proteins 1 or 2 (HEXIM1 or
HEXIM2), La-related protein 7 (LARP7) and the
methylphosphate capping enzyme (MePCE) (11). In this
large complex, HEXIM proteins inhibit the kinase activity
of CDK9 (5,12). Whereas the 7SK snRNP, which is
loosely associated with chromatin, is extracted easily
with low salt (10mM), the P-TEFb that is engaged in
transcription, is bound to chromatin, and thus requires a
higher salt concentration (>0.15M) for its extraction (13).
Depending on the cell type, up to 90% of P-TEFb is
found in the 7SK snRNP, and the equilibrium between
active and inactive complexes (P-TEFb equilibrium) deter-
mines the overall transcriptional activity of the cell (5).
Many stresses such as UV light, heat, inhibition of tran-
scription by Actinomycin D, DRB or ﬂavopiridol, histone
deacetylase inhibitors (HDACis) such as tricostatin A
(TSA), suberoylanilide hydroxamic acid (SAHA) as well
as speciﬁc intracellular signaling cascades can disrupt the
7SK snRNP and activate P-TEFb (6,14–17). Although
precise molecular mechanisms leading to the disruption
of 7SK snRNP and the release of P-TEFb remain to be
elucidated, multiple post-transcriptional modiﬁcations of
7SK snRNP components are involved. For instance,
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HMBA and UV light activate PP2B (Ca++/Calmodulin-
dependent protein phosphatase) and PP1a, which can
dephosphorylate threonine at position 186 (T loop) in
CDK9, and thus release P-TEFb (18,19). In a different
cellular context, HMBA also activates the phosphatidy-
linositol-3-kinase (PI3K)/Akt-signaling pathway, which
antagonizes the interaction between P-TEFb and
HEXIM1 through phosphorylation of the threonine and
serine at positions 270 and 278 of HEXIM1, respectively.
T-cell antigen receptor (TCR) signaling also disrupts the
7SK snRNP by a signaling cascade that activates Erk,
although its phosphorylation target remains unknown
(20). In addition to these kinases and phosphatases, the
acetylation of CycT1 contributes to this release, which
could explain additional effects of HDACis on the
activity of P-TEFb (21,22). Therefore, distinct molecular
pathways target 7SK snRNP subunits to release the active
free P-TEFb in cells.
Since P-TEFb also serves as the host cellular cofactor
for HIV transcription and replication, studying its regula-
tion is particularly important for the development of new
antiviral therapies (16,23–27). Although the highly active
antiretroviral therapy (HAART) reduces levels of HIV
RNA below detection, persistence of latently infected
cells prevents the cure of AIDS. To eradicate this reser-
voir, it is critical to reactivate viral replication and to elim-
inate these latently infected cells. Signals that activate
NF-kB and P-TEFb, two critical complexes for HIV tran-
scription, might accomplish this task. Indeed, protein
kinase C (PKC) agonists activate both of them and can
reactivate HIV replication (28–30). In this study, we found
that PKC phosphorylates HEXIM1 on a speciﬁc serine
residue, which increases not only levels of free P-TEFb
but also transcription of a target gene. We focused on
PKCy, which is the major PKC isoform found in T cells
(31–36).
MATERIALS AND METHODS
Cell lines, reagents and antibodies
Jurkat T cells were grown in RPMI containing 10% FCS at
37C with 5% CO2. 293T and Hela cells were grown in
DMEM containing 10% FCS at 37C with 5% CO2. Che-
lerythrine chloride and phorbol myristyl acetate (PMA)
were purchased from Sigma-Aldrich. Bisindolylmaleimide
family compounds were purchased from Calbiochem.
Flavopiridol was obtained from the AIDS Reference and
Reagent Program (NIH). The anti-CycT1(sc-10750),
anti-CDK9 (sc-484) antibodies were obtained from Santa
Cruz Biotechnology. The anti-HEXIM and anti-tubulin
antibodies were obtained from Abcam. The anti-PKCy
antibody was purchased from Cell Signaling Technologies.
The anti-Flag M2 (F3165) antibody and the anti-Flag M2
agarose beads (A2220) were purchased from Sigma-
Aldorich. The anti-CD3 and anti-CD28 antibodies were
purchased from Pharmingen. Afﬁnity puriﬁed anti-
phosphoryated HEXIM1 antibody was raised in rabbits
injected with peptide from HEXIM1 from positions 150
to 165, where the serine at 158 was replaced with
phosphoserine, and afﬁnity-puriﬁed using peptide antigen-
conjugated columns.
Plasmids
Plasmids directing the expression of dominant negative
(DN) and constitutively active (CA) PKCy proteins were
a generous gift from Art Weiss (33). The pG5TKLuc
reporter plasmid was described previously (37). The
pFLAG-CMV-2.HEXIM1 plasmid was described previ-
ously (38). To construct the plasmid coding for the
mutant ﬂag-HexS158A proteins, the pFLAG-CMV-
2.HEXIM1 plasmid was subjected to site directed muta-
genesis with the QuickChange II XL Site-Directed
Mutagenesis Kit (Stratagene) (39).
In vitro kinase assays
An amount of 16 ml kinase reactions containing puriﬁed
recombinant P-TEFb with human DSIF or RNA poly-
merase II (RNAPII) as substrates were carried out in
30mM KCl, 20mM HEPES pH 7.6, 7mM MgCl2,
30 mM ATP, 1.3mCi of [g-32P]-ATP (Amersham), 1 mg
BSA per reaction and the indicated amounts of
HEXIM1 proteins. T7-transcribed 7SK snRNA or
double-stranded (ds) RNA oligonucleotides were added
last to the pre-incubation mixture. All reactions were
incubated for 10min at 23C prior to the addition of
ATP. The kinase reactions were then incubated for
20min at 30C and then stopped by the addition of
sodium dodecyl sulfate–polyacrylamide gel electrophor-
esis (SDS–PAGE) loading buffer. Reaction products
were resolved by 9% SDS–PAGE. The dried gel was sub-
jected to autoradiography and quantiﬁed with a Packard
InstantImager. The PKC in vitro kinase assays (IVKAs)
using wild-type or mutant HEXIM1 proteins as substrates
were performed in 50 ml reactions in a buffer containing
25mMHEPES (pH 7.5), 10mMMgCl2, 200 mMATP and
2 mCi of [g-32P]ATP. All reactions were incubated for
15min at 30C, stopped by the addition of 2 SDS–
PAGE loading buffer. Fifteen microliters of each
reaction mixture was subjected to 10% SDS–PAGE
followed by autoradiography.
In vivo kinase assays
HeLa cells were seeded in 100-mm plates and transfected
with 3 mg of ﬂag-HEXIM1 expression plasmids. Twenty-
four hours after transfection, cells were serum-deprived
for 12 h and labeled with [32P] orthophosphate (300mCi/
ml) for 1.5 h at 37C with or without a PKC inhibitor
chelerythrine chloride (5 mM). Next, cells were washed
with ice-cold PBS, resuspended in TNE buffer (10mM
Tris–HCl, 150mM NaCl, 1mM EDTA, complete
EDTA-free protease inhibitor mixture (Roche Molecular
Biochemicals), phosphatase inhibitor mixture (Sigma)
containing 1% NP-40 and lysed for 1 h. Following centri-
fugation, ﬂag-HEXIM1 proteins were immunopre-
cipitated using FLAG M2 agarose beads, separated by
10% SDS–PAGE and visualized by autoradiography.
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Phosphorylation of HEXIM1 and repuriﬁcation
Phosphorylation was carried out under identical condi-
tions as in kinase assay described above, except that
1mM ATP was used, and incubation time was at least
6 h at 37C. After phosphorylation, His epitope-tagged
HEXIM1 proteins were repuriﬁed by Ni–NTA
chromatography.
Electrophoretic mobility shift assay
For electrophoretic mobility shift assay (EMSA) in
Figure 2, 12 ml reactions were carried out in 25mM
HEPES, pH 7.6, 15% glycerol, 60mM KCl, 0.1mM
EDTA, 5mM DTT, 0.01% NP-40 and included 200 ng
recombinant HEXIM1, P-TEFb and various RNA or
DNA oligonucleotides as indicated. Reactions were
incubated at room temperature for 15min and resolved
by 6% PAGE at 4C for 1.5 h at 6W. Proteins were
visualized by silver staining. For EMSA in Figure 3,
12 ml reactions were carried out in 25mM HEPES, pH
7.6, 15% glycerol, 60mM KCl, 0.1mM EDTA, 5mM
DTT, 0.01% NP-40 and included 200 ng recombinant
HEXIM1, P-TEFb and a-32P-labeled 7SK snRNA.
Reactions were incubated at room temperature for
15min and resolved by 6% PAGE at 4C for 1.5 h at
6W. The free probe and RNA–protein complexes were
visualized by autoradiography.
Glycerol gradients
Glycerol gradients (10–30%) were established by pipeting
2ml of each glycerol fraction (10, 15, 20, 25 and 30% v/v)
in buffer A (20mM HEPES (pH7.9), 0.3M KCl, 0.2mM
EDTA, 0.1% NP40) into centrifugation tubes (Beckman
331372). Gradients were formed by standing for 6 h at
4C. Stimulated or unstimulated Jurkat T cells transfected
or not with corresponding plasmids were lysed in 0.6ml
of buffer A containing protease inhibitor cocktail
(Fermentas) and an RNase inhibitor (Roche) for 30min
at 4C. Lysates were centrifuged at 10 000g 14 000 rpm for
10min and supernatants were loaded into tubes with pre-
formed glycerol gradients. Protein complexes were then
fractionated by centrifugation in an SW4T1 rotor
(Beckman) at 38 000 rpm<AQ10> for 21 h. Ten fractions
(1ml) were collected, precipitated with trichloracetic acid
and analyzed with the indicated antibodies by western
blotting. Fractions with detectable bands are presented
in Figures 5 and 6. Band intensities were quantiﬁed by
LI-COR Odyssey Imaging System and plotted as
indicated in Figures 5 and 6.
Cell fractionation
Jurkat T cells, conﬂuent in 12-well plates, were pelletted
and washed once in ice-cold PBS, 0.1% PMSF. Cells were
resuspended in 70 ml of cold buffer A (10mM HEPES,
15mM KCl, 2mM MgCl2, 0.1mM EDTA, 1mM DTT,
0.1% PMSF, 40U/ml RNaseOUT (Invitrogen)) and
incubated on ice with occasional vortexing for 10min.
Cell lysates were spun for 5min at 4000 rpm in a cold
table microcentrifuge to isolate the 7SK snRNP. Nuclei
were resuspended with 70 ml of cold buffer B (10mM
HEPES, 2mM MgCl2, 0.5mM EDTA, 1mM DTT,
420mM NaCl, 0.5% NP-40, 0.1% PMSF, 40U/ml
RNaseOUT (Invitrogen)) and incubated on ice with occa-
sional vortexing for 10min. Cell lysates were spun for
5min at 4000 rpm in a cold table microcentrifuge to
isolate the fraction containing the free P-TEFb.
Transient transfection and reporter gene assays
293T or HeLa cells were seeded into 24-well plates 12 h
prior to transfection using Extreme (Roche). Luciferase
enzymatic assays were performed as described previously
(15,40). Jurkat T cells were transiently transfected with
mutant PKCy expressing plasmids using Extreme
(Figure 5) or by electroporation (Biorad, Figure 6) at
250V/960 mF as described previously (33).
RESULTS
PKC phosphorylates HEXIM1 on the serine
at position 158 (S158)
It is well established that activation of cellular-signaling
pathways induces a disruption of the 7SK snRNP via
post-transcriptional modiﬁcations of its individual com-
ponents (14,17,18,20,22). In particular, phosphorylation
and acetylation play important roles in the removal and
activation of P-TEFb from the 7SK snRNP. To investi-
gate potential additional phosphorylation targets, we
aligned primary amino acid sequences of HEXIM
proteins from human, mouse, chicken and ﬁsh. This com-
parison revealed that there is an evolutionally conserved
region from positions 150 to 165, in which the serine at
position 158 (S158) lies in a canonical PKC phosphoryl-
ation site (RxxS/TxK/R, Figure 1A) (41). Since this highly
basic region also interacts with 7SK snRNA (42–45), the
addition of a negative charge by phosphorylation of S158
should decrease the ability of HEXIM1 to bind to RNA.
To this end, we examined whether HEXIM1 can be
phosphorylated by PKC in vitro and in vivo. First, ﬂag
epitope-tagged wild-type (WT) HEXIM1 (ﬂag-Hex)
protein was expressed in HeLa cells. Cells were labeled
with [32P] orthophosphate with or without the
PKC-inhibitor chelerythrine chloride (5mM) for 1.5 h
prior to cell lysis followed by immunoprecipitation with
anti-ﬂag antibodies and autoradiography. As presented in
Figure 1B, ﬂag-Hex was heavily phosphorylated ((P)Hex,
lane 2, upper panel). The amount of phosphorylated
HEXIM1 protein was dramatically reduced when cells
were incubated with this PKC inhibitor (Figure 1B, lane
3, upper panel). The speciﬁcity and the efﬁciency of
immunoprecipitations were conﬁrmed by western
blotting (Figure 1B, bottom panel, Hex). IVKAs using
puriﬁed PKC and HEXIM1 proteins expressed and
puriﬁed from Escherichia coli as GST-fusion proteins
(Figure 1C) or the ﬂag-Hex protein expressed in HeLa
cells and immunoprecipitated with anti-ﬂag antibodies
(Figure 1D) further conﬁrmed that HEXIM1 can be
phosphorylated by PKC (Figure 1C and D, upper
panels, lanes 1, (P)Hex). Of note, under these conditions
P-TEFb cannot phosphorylate HEXIM1 and PKC did
not phosphorylate CDK9 or CycT1 (data not presented).
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Changing the S158 in HEXIM1 to alanine (HexS158A)
almost completely abolished this phosphorylation by
PKC (Figure 1C and D, upper panels, lanes 2, (P)Hex),
indicating that no other residues in HEXIM1 were
phosphorylated by PKC. We conclude that PKC phos-
phorylates S158 in HEXIM1.
Phosphorylated HEXIM1 fails to bind to 7SK snRNA
and to inhibit P-TEFb
Next, we examined effects of HEXIM1 phosphorylation
on its ability to interact with RNA and to inhibit P-TEFb
activity. His epitope-tagged WT HEXIM1 and mutant
HEXIM1 (S158A) proteins (his-Hex and his-HexS158A)
were expressed and puriﬁed from E. coli. Recombinant
proteins were phosphorylated with the puriﬁed PKC
protein in an in vitro reaction with cold ATP, and then
repuriﬁed by Ni–NTA afﬁnity chromatography. A
parallel phosphorylation experiment with [g-32P]-ATP
conﬁrmed that the WT his-Hex but not mutant
his-HexS158A proteins were phosphorylated by PKC
under these conditions (Figure 2A, lanes 1–4, (P)Hex).
To examine interactions between HEXIM1 and RNA,
the in vitro phosphorylated and WT HEXIM1 proteins
were tested for RNA binding in EMSAs. Increasing
amounts of unlabeled dsRNA were incubated with
200 ng of WT (Figure 2B, lanes 2–6) or phosphorylated
(P) (Figure 2A, lanes 8–12) HEXIM1 (Hex and (P)Hex)
proteins for 15min at room temperature. RNA–protein
complexes were separated by a native PAGE followed
by silver staining to detect free HEXIM1 proteins (Hex)
and HEXIM1 associated with dsRNA (Hex:dsRNA). As
presented in Figure 2B, the WT his-Hex protein exhibited
a mobility shift when incubated with dsRNA (lanes 2–6,
Hex:dsRNA) whereas no apparent mobility shifts were
observed when dsRNA was added to the phosphorylated
his-(P)Hex protein (lanes 8–12, (P)Hex). A parallel experi-
ment with the mutant his-HexS158A protein demon-
strated that it interacted with dsRNA and there was no
difference in this mobility shift whether or not the proteins
had been pre-incubated with PKC and ATP (data not
presented).
An EMSA using recombinant GST-Hex fusion pro-
teins and a-32P-labeled 7SK snRNA gave similar results
(Figure 3). Whereas the WT GST-Hex and mutant GST-
HexS158A proteins bound to 7SK snRNA in the presence
or absence of P-TEFb, changing the S158 to glutamic acid
(S158E) diminished the ability of HEXIM1 to interact
with 7SK snRNA (Figure 3, lanes 1–6). The slight
residual binding of the mutant GST-HexS158E protein
to 7SK snRNA could be due to differences in the
negative charge between the substituted glutamic acid
and the phospho-serine in the phosphorylated HEXIM1
Figure 1. HEXIM1 is phosphorylated in vivo and is a substrate of PKC in vitro. (A) Serine at position 158 in HEXIM1 is an evolutionary conserved
residue in a consensus PKC phosphorylation sequence. Primary sequence of the human HEXIM1 protein from positions 150 to 165 is aligned with
the corresponding positively charged regions of HEXIM proteins from mouse, chicken, zebraﬁsh and puffer ﬁsh, respectively. Whereas white letters
in a black background indicate amino acid identity, black letters in a gray background indicate amino acid similarity. The consensus PKC phos-
phorylation sequence is presented above the alignment. (B) The PKC inhibitor chelerythrine chloride reduces the phosphorylation of HEXIM1
in vivo. Flag epitope-tagged HEXIM1 proteins (Hex) were expressed and labeled with [g-32P]-ATP in HeLa cells and immunoprecipitated with
anti-ﬂag antibodies. Cells were also treated with chelerythrine chloride (PKC inhibitor). Upper and lower panels contain phosphorylated chimeras
(autoradiograph, (P)Hex) and input (25%) of proteins (western blot, Hex), respectively. (C) PKC phosphorylates serine at position 158 in HEXIM1,
which was puriﬁed from E. coli, in vitro. WT GST-HEXIM1 and mutant GST-HEXIM1 (S158A) chimeras (GST-Hex and GST-HexS158A,
respectively), which were extensively puriﬁed from E. coli, were subjected to IVKAs by PKC as indicated. Upper and lower panels contain
phosphorylated chimeras (autoradiograph, (P)Hex) and the input (25%) of proteins (western blot, Hex), respectively. (D) PKC phosphorylates
serine at position 158 in HEXIM1, which was puriﬁed from HeLa cells, in vitro. Flag epitope-tagged WT HEXIM1 and mutant HEXIM1 (S158A)
proteins (Hex and HexS158A, respectively), which were expressed in HeLa cells were immunoprecipitated with anti-ﬂag antibodies, and subjected to
IVKAs by PKC. Upper and lower panels contain phosphorylated chimeras (autoradiograph, (P)Hex) and the input (25%) of proteins (western blot,
Hex), respectively.
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protein. These results indicate that HEXIM1, which is
phosphorylated at S158 loses its ability to interact
with RNA.
In addition, the WT and phosphorylated HEXIM1
proteins were examined for their ability to inhibit CDK9
kinase activity in the presence of 7SK snRNA. We per-
formed P-TEFb kinase assays by incubating the puriﬁed
recombinant P-TEFb complex (CDK9 and CycT1) with
DSIF and [g-32P]-ATP in the absence (Figure 2C, lane 1,
DSIF) or presence of HEXIM1 and/or 7SK snRNA
(Figure 2C, lanes 2–14, DSIF). Indeed, whereas CDK9
kinase activity was inhibited by the addition of increas-
ing amounts of WT his-Hex protein and 7SK snRNA
(Figure 2C, lanes 7–9, DSIF), the phosphorylated his-
(P)Hex protein failed to inhibit P-TEFb even in the
presence of dsRNA or 7SK snRNA (Figure 2C, lanes
9–14, DSIF). HEXIM1 or 7SK snRNA alone had no in-
hibitory effect on P-TEFb (Figure 2C, lanes 2–4, DSIF).
We conclude that the phosphorylated HEXIM1 protein
neither binds to RNA nor inhibits P-TEFb.
PKCh stimulates the activity of P-TEFb and NF-kB
The above in vitro data implicated PKC in the phosphor-
ylation of S158 in HEXIM1, which inactivated its ability
to bind to 7SK snRNA and to inhibit P-TEFb. Next, we
sought to determine the functional consequence of this
HEXIM1 phosphorylation in vivo. As presented in
Figure 1B, the treatment of cells with the pan-PKC inhibi-
tor chelerythrine chloride inhibited HEXIM1 phosphoryl-
ation. Surprisingly, it also inhibited the phosphorylation
of RNAPII (data not presented), which prompted us to
examine if speciﬁc PKC inhibitors could also inhibit
CDK9. Indeed, Ro-31-8220, one of the commonly used
pan-PKC inhibitors exhibited strong inhibitory effects on
PKC and CDK9 with similar IC50s (between 1 and
10 nM), when used in PKC- and P-TEFb-speciﬁc kinase
assays using HEXIM1 and RNAPII as substrates, respect-
ively (Supplementary Figure S1A and B). Indeed, other
bisindolylmaleimide family of PKC inhibitors also in-
hibited CDK9 with IC50s comparable to those for PKC
Figure 2. HEXIM1, which is phosphorylated on the serine at position 158, neither binds to RNA nor inhibits P-TEFb. (A) Only the WT HEXIM1
protein is phosphorylated by PKC in vitro. Puriﬁed His epitope-tagged WT HEXIM1 and mutant HEXIM1 (S158A) proteins (Hex and HexS158A)
were incubated with native PKC catalytic subunit puriﬁed from rat brain in the presence of [g-32P] ATP for indicated times at 30C. The
phosphorylated HEXIM1 protein ((P)Hex) was detected by autoradiography. (B) Only the unmodiﬁed HEXIM1 protein binds to RNA.
Indicated amounts of WT and in vitro PKC-phosphorylated HEXIM1 proteins were incubated with dsRNA for 10min. at room temperature.
RNA:protein mixtures were then separated by non-denaturing gels, and visualized by silver staining. The positions for Hex:dsRNA complex and free
Hex protein are indicated on the left of the gel. (C) The phosphorylated HEXIM1 protein no longer inhibits the kinase activity of CDK9. IVKAs
were performed by incubating puriﬁed P-TEFb with DSIF as a substrate in the presence of WT HEXIM1 (lane 2, Hex) or the phosphorylated
HEXIM1 protein alone (lane 3, (P)Hex) or in the presence of dsRNA or 7SK snRNA (lanes 4 and 5, dsRNA and 7SK) or with combinations of
increasing amounts of HEXIM1 and 7SK snRNA (lanes 6–8, 7SK+Hex), phosphorylated HEXIM1 proteins (lanes 9–11, dsRNA+(P)Hex; or, lanes
12–14, 7SK+(P)Hex). Phosphorylated DSIF was visualized by autoradiography.
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(Supplementary Figure S1C and D). In contrast, ﬂavo-
piridol, a highly potent CDK9 inhibitor, did not inhibit
PKC within the range of concentration required to inhibit
CDK9 (Supplementary Figure S1C).
Since PKC inhibitors inhibit CDK9, we could not use
them for the analysis of P-TEFb-dependent transcription
in cells. Therefore, we examined directly effects of PKC on
the activity of a reporter gene. To this end, we employed a
thymidine kinase promoter-luciferase plasmid target that
also contained ﬁve repeats of the Gal4 DNA-binding
sequence (pTG5Luc), and a plasmid effector encoding
the p65 (RelA) subunit of NF-kB linked to the Gal4
DNA-binding motif (Gal.p65). Previously, we demon-
strated that this Gal.p65 chimera depended entirely on
P-TEFb for its activity (46).
Although there are at least 15 isoforms of PKC in
humans, we focused on PKCy, which is expressed pre-
dominantly in T cells where HIV replicates (33–36). In
addition, PKCy can be found in the nucleus where it func-
tions in transcriptional regulation (47). To this end, we
coexpressed pTG5Luc and the Gal.p65 chimera in the
presence or absence of CA or kinase-negative (DN)
mutant PKCy proteins (CA-PKCy and DN-PKCy) in
293T cells. Whereas the expression of CA-PKCy
stimulated the activity of the Gal.p65 chimera 3-fold
(Figure 4A, bars 2 and 3), the expression of DA-PKCy
had no or slightly negative effects (Figure 4A, bars 2 and
4). Next, we examined whether the exogenous expression
of the WT HEXIM1 or mutant HEXIM1 (S158A)
proteins blocks this PKCy-dependent activation. Indeed,
the WT ﬂag-Hex and mutant ﬂag-HexS158A proteins
inhibited the CA-PKCy-dependent activation of the
Gal.p65 chimera on pG5Luc to a lesser and greater
extent, respectively (Supplementary Figure S2, bars 3
and 4 and Figure 4B, bars 2–5). In the resting state, the
WT HEXIM1 and mutant HEXIM1 (S158A) proteins
bind to 7SK snRNA. Whereas CA-PKCy can phosphor-
ylate the WT protein at S158, it cannot phosphorylate the
mutant HEXIM1 (S158A) protein. Thus, the WT
HEXIM1 dissociates from 7SK snRNA, but the mutant
HEXIM1 (S158A) protein remains bound to 7SK snRNA,
thus exhibiting a more potent inhibitory effect on
CA-PKCy-mediated stimulation of p65 activity. Neither
mutant PKCy nor HEXIM1 proteins altered the expres-
sion of our protein effectors (Figures 4A and B, lower
panels, Gal.p65, PKCy, Hex). Thus, PKCy increases the
activity of NF-kB by targeting the 7SK snRNP.
Finally, we examined if the activation of endogenous
PKC-signaling pathways can also stimulate P-TEFb.
First, 293T cells, which coexpressed pGT5luc and the
Gal.p65 chimera, were treated with the PKC agonist
PMA (10 nM) for 24h prior to our luciferase assays.
PMA increased Gal.p65-dependent luciferase activity
6-fold (Figure 4C, bars 1 and 2). Expressing the mutant
ﬂag-HexS158A (bar 3) or DN-PKCy (lane 4) proteins abol-
ished this stimulatory effect of PMA. Similar results were
observed when the Gal4–CycT1 fusion protein was used as
the protein effector instead of the Gal.p65 chimera (data
not presented). We conclude that the phosphorylation of
HEXIM1 at S158 by PKCy activates P-TEFb in vivo.
CA-PKCh shifts the P-TEFb equilibrium
Experiments presented in Figure 2 indicated that the
phosphorylated HEXIM1 protein not only fails to bind
to 7SK snRNA but loses its ability to inhibit the kinase
activity of P-TEFb, which stimulates transcription. To
investigate functional consequence of this HEXIM1 phos-
phorylation, we raised phospho-speciﬁc polyclonal
antibodies against a HEXIM1 peptide containing the phos-
phorylated serine at position 158. These anti-
phospho-HEXIM1 ((P)Hex) antibodies were further
puriﬁed from serum by phosphopeptide-afﬁnity chroma-
tography. Their speciﬁcity was conﬁrmed with puriﬁed
GST-Hex and GST-HexS158A chimeras, which were
pre-incubated with PKC and unlabeled ATP, by western
blotting (Figure 5A, lane 2, (P)Hex). Next, we determined
if PKCy can phosphorylate HEXIM1 and release P-TEFb
from the 7SK snRNP. Indeed, expressing the CA-PKCy in
Jurkat T cells, levels of phosphorylated HEXIM1 protein
increased 5-fold, as determined with anti-(P)Hex antibodies
by western blotting (Figure 5A, center, middle panel). We
conclude that PKCy can phosphorylate S158 in HEXIM1.
Previously, we established a method to separate quickly
the 7SK snRNP from the free P-TEFb using step-wise frac-
tionation of cell lysates (13). Using this method, we
analyzed P-TEFb and HEXIM1 in the presence and
absence of CA-PKCy in Jurkat T cells. Cells were lysed
ﬁrst in low salt (10mM KCl) to extract the 7SK snRNP
(free nuclear fraction), then in a high salt (0.3M KCl)
buffer to extract free P-TEFb (chromatin bound fraction).
Figure 3. Changing S158 to glutamic acid reduces the binding of
HEXIM1 and P-TEFb to 7SK snRNA in vitro. Recombinant
GST-Hex, GST-HexS158A and GST-HexS158E proteins alone or
with P-TEFb were incubated with a-32P-labeled 7SK snRNA. RNA–
protein complexes were separated by non-denaturing PAGE and
visualized by autoradiography. Arrows to the left indicate the free
7SK snRNA, HEXIM1-7SK snRNA complex or 7SK snRNP.
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Since up to 6-fold more HEXIM1 was detected in the high
salt fraction, the expression of CA-PKCy increased levels of
free P-TEFb (Figure 5A, right panel, lanes 2 and 4, H).
Glycerol gradient sedimentation also indicated that more
CycT1, CDK9 and HEXIM1 were removed from the 7SK
snRNP when CA-PKCy was expressed in cells (Figure 5B,
left panel, lanes 1–4, CA-PKCy, free). The quantiﬁcation of
CycT1, HEXIM1 and Cdk9 in fractions corresponding to
free P-TEFb (lanes 1–3) and 7SK snRNP (lanes 5–7)
revealed that the expression of CA-PKCy increased ratios
between free P-TEFb and 7SK snRNP 2-, 1.7- and 1.8-fold,
respectively (Figure 5B, center panel). These results indicate
that CA-PKCy phosphorylates HEXIM1, which shifts the
P-TEFb equilibrium towards increased levels of free
P-TEFb in cells.
T-cell receptor engagement also shifts the P-TEFb
equilibrium in cells
To conﬁrm that cellular-signaling pathways that activate
endogenous PKCy also activate P-TEFb via the phos-
phorylation of HEXIM1 and disruption of the 7SK
snRNP, we analyzed changes in the P-TEFb equilibrium
by stimulating Jurkat T cells with PMA or by engaging the
TCR with anti-CD3 and anti-CD28 antibodies. Indeed,
cell fractionation analyses indicated that PMA and TCR
signaling increased the phosphorylation of HEXIM1
((P)Hex, Figure 6A, left, lower panel, lanes 3 and 6) and
the removal of HEXIM1 from the 7SK snRNP up to
8-fold (Hex, Figure 6A, left, upper panel, lanes 4 and 6,
Hex and (P)Hex and right panel, bars 1–3). The expression
of DN-PKCy inhibited this shift of HEXIM1, further
conﬁrming the involvement of PKCy in this process
(Figure 6A, left panels, lanes 7 and 8, Hex and (P)Hex
and right panel, bar 4). Glycerol gradient analyses also
supported this ﬁnding (Figure 6B, left panels, lanes 1–4,
free). Indeed, just 30min after the addition of anti-CD3
and anti-CD28 antibodies to Jurkat cells, more CycT1 was
detected in earlier fractions corresponding to free P-TEFb
(Figure 6B, left, top and middle panels, lanes 1–4, CycT1,
free). The expression of DN-PKCy also inhibited this
shift (Figure 6B, left bottom panel). Indeed, the addition
of anti-CD3 and anti-CD28 antibodies increased the ratio
between free P-TEFb and 7SK snRNP 3.3-fold, which was
decreased to 1.9-fold by DN-PKCy (Figure 6, right panel).
Figure 4. PKCy stimulates NF-kB activity, which is blocked by mutant HEXIM1 (S158A) and/or a DN PKCy proteins. (A) CA and DN PKCy
proteins (CA-PKCy and DN-PKCy) affect the activity of NF-kB (Gal.p65). These proteins were coexpressed with p5GTLuc in 293T cells. Luciferase
activities were measured 48 h after the transfection. They are presented as fold activation over the value obtained with the plasmid target and
equivalent amounts of the empty plasmid vector (lane 1). The expression of the Gal.p65 chimera (middle panel, Gal.p65) and PKCy (bottom panel,
PKCy) was conﬁrmed with anti-Gal4 and anti-PKCy antibodies by western blotting. Error bars represent standard errors from three experiments
performed in duplicate. (B) Increasing amounts of mutant HEXIM1 (S158A) inhibit effects of CA-PKCy. These proteins, with increasing amounts of
the mutant HEXIM1 (S158A), were coexpressed with p5GTLuc in 293T cells. Luciferase assays were performed as described above. The expression
of Gal.p65, PKCy and the mutant HEXIM1 (S158A) proteins was conﬁrmed with anti-Gal4, anti-PKCy, anti-Flag antibodies by western blotting,
respectively. Error bars are as in (A). (C) Phorbol esters also activate NF-kB, which is blocked by mutant HEXIM1 (S158A) and/or a DN-PKCy
proteins. p5GTLuc was expressed alone or with these proteins in 293T cells. Twenty-four hours after the transfection, cells were untreated (lane 1) or
treated with PMA (20 nM)(lanes 2–4) for additional 24 h before performing luciferase assays. The expression of proteins was conﬁrmed with
anti-Gal4, anti-PKCy, anti-ﬂag antibodies by western blotting, respectively. Errors are as in (A).
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HEXIM1 and Cdk9 exhibited similar patterns (data not
presented). A similar result was obtained with another
PKC agonist bryostatin-1 (data not presented). We
conclude that the induction of PKC signaling via
phorbol esters or TCR engagement leads to the phosphor-
ylation of HEXIM1, which shifts the P-TEFb equilibrium
towards more free P-TEFb in cells.
DISCUSSION
Our results demonstrate that the phosphorylation of
HEXIM1 at S158 by PKCy shifts the P-TEFb equilibrium
away from the 7SK snRNP. Although we presented data
on PKCy, we also performed limited experiments with
other PKC isoforms, namely PKCa, PKCd and PKCi.
In vitro, all of these three PKC isoforms and possibly
others can phosphorylate S158 in HEXIM1. Of these,
PKCi is found predominantly in the nucleus, where it
also activates the activity of NF-kB (48,49). Thus, it is
very likely that many PKC isoform that can access 7SK
snRNP in the nucleus will activate P-TEFb by this mech-
anism. In this study, we concentrated on PKCy because of
previous reports of its involvement in TCR signaling,
nuclear localization and transcriptional activity in T cells
(33,34,36,47). While we were impressed by how conserved
this consensus PKC target site is during evolution of
HEXIM1 and is also present in HEXIM2, we found no
other target sequence for PKC phosphorylation on other
subunits of 7SK snRNP, which include CycT1 and CDK9.
We were also surprised that thus phosphorylated, (P)Hex,
like free P-TEFb, moved to chromatin from the soluble
nuclear fraction. This movement could represent a con-
formational change in the protein and/or association
with a new set of proteins that interact with chromatin.
Of note, others had also noted this association between
HEXIM1 with chromatin (50,51). Indeed, this chromatin-
associated HEXIM1 protein, when dephosphorylated,
could play an active role by helping to remove P-TEFb
from abortive or arrested transcription as well as after
termination and 30-end processing events.
Figure 5. The CA-PKCy protein phosphorylates HEXIM1, which releases free P-TEFb. (A) The CA PKCy protein (CA-PKCy) phosphorylates
HEXIM1 and leads to its release in cells. Left panel: Evaluation of antibodies against HEXIM1, which is phosphorylated on the serine at position
158 ((P)Hex). IVKAs were performed with puriﬁed PKC and WT HEXIM1 or mutant HEXIM1 (S158A) proteins (Hex or HexS158A) and
non-radioactive ATP as the substrate. Protein complexes were then separated by SDS–PAGE, followed by western blotting with
anti-phospho-HEXIM1 ((P)Hex, upper panel) and anti-HEXIM1 (Hex, lower panel) antibodies. Center and right panels: Cell fractionation
analyses were performed with Jurkat T cells, which expressed the empty plasmid vector () or the CA PKCy protein (CA-PKCy). Complexes,
which were bound loosely or tightly to chromatin were extracted with buffers containing low (L,10mM) and high (H, 300mM) salt concentrations.
Center panel: Phosphorylated and unphosphorylated HEXIM1 proteins (middle panel, (P)Hex; bottom panel, Hex) in the high salt (H) fraction was
detected with anti-phospho-HEXIM1 and anti-HEXIM1 antibodies, respectively. Band intensities were quantiﬁed (top panel) and are presented as
fold increase over the value obtained with Jurkat T cells, which expressed only the empty plasmid vector. Right panel: After fractionation, HEXIM1
was detected with anti-HEXIM1 antibodies by western blotting (lower panel, Hex). The release of HEXIM1 to chromatin (H, high salt) was
quantiﬁed relative to the value obtained with Jurkat T cells, which expressed the empty plasmid vector only (Hex release). (B) The CA PKCy
protein (CA-PKCy) releases of P-TEFb and HEXIM1 from 7SK snRNP. Left panel: Glycerol gradient sedimentation was performed with Jurkat T
cells, which expressed the empty plasmid vector (upper panels, ) or CA-PKCy (lower panels, CA-PKCy). Twenty-four hours after transfection, cell
lysates were subjected to glycerol gradient (10–30%) sedimentation. Fractions were separated by SDS–PAGE and analyzed with anti-CycT1 (top
panels), anti-HEXIM1 (middle panels) and anti-CDK9 (bottom panels) antibodies by western blotting. Center Panel: Band intensities in fractions
corresponding to free P-TEFb (lanes 1–3) and 7SK snRNP (lanes 5–7) were quantiﬁed and ratios between these two groups were calculated and
plotted as a fold-increase over values obtained with untransfected Jurkat cells. Right panel: The expression of CA-PKCy was conﬁrmed with
anti-PKCy antibodies by western blotting.
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Changes in the P-TEFb equilibrium via intracellular sig-
naling represent important steps in the global control of
transcription elongation. While no uniﬁed mechanisms for
the sequestration of P-TEFb exist, distinct post-transla-
tional modiﬁcation of 7SK snRNP components, such as
phosphorylation and acetylation play important roles in
this process. For instance, our previous studies indicated
that HBMA stimulates PI3K/Akt kinase pathway and
phosphorylates HEXIM1 on the threonine and serine at
positions 270 and 278 (14). Karn and colleague
demonstrated that P-TEFb release via TCR signaling
also involves the Erk kinase, although its exact target on
the 7SK snRNP was not identiﬁed (20). In the study pre-
sented here, we observed a quantitatively similar release of
P-TEFb via small molecule PKC agonists (i.e. PMA,
bryostatin-1) and TCR signaling. However, we did not
detect any phosphorylation of HEXIM1 by the Erk
kinase (data not presented). This ﬁnding is not surprising,
as none of our phosphorylation sites represents a canon-
ical Erk phosphorylation motif (SPKTP) (52). Neverthe-
less, our results are in agreement with their observation
that these agonists increase greatly the transcription from
the HIV LTR (20). In addition to these phosphorylation
events, PP2B and PP1a can disrupt the 7SK snRNP by
dephosphorylating the threonine at position 186 (T loop)
of CDK9 (18). Since some HDACis activate P-TEFb, the
acetylation of CycT1 also plays an important role in the
release of free P-TEFb. Indeed, thus acetylated, CycT1
preferentially associates with BRD4 (21,22). Thus,
different stimuli disrupt the 7SK snRNP for signal-
dependent stimulation of transcription elongation. Most
likely, these stimuli set up new P-TEFb equilibria, each of
which has small effects on global transcription. However,
separate and convergent pathways should act synergistic-
ally with far greater effects on levels of free P-TEFb,
thereby increasing transcription globally, which may
result in cell growth and proliferation of target cells.
Besides leading to increased levels of free P-TEFb and
activation of NF-kB-dependent transcription, there exist
many publications on the role of PKC in biology and HIV
replication, which include positive and negative effects
(53–60). However, studies using speciﬁc PKC inhibitors
must be reexamined in light of our ﬁndings because
these agents, particularly bisindolylmaleimide group of
compounds, exhibit very potent inhibitory effects on
CDK9 (Supplementary Figure S1). In the case of Ro-31-
8220, its IC50 for P-TEFb was similar to that for PKC.
The inhibition of P-TEFb by Ro-31-8220 was also inde-
pendent of the concentration of ATP, suggesting that it is
a non-competitive inhibitor (data not presented).
Importantly, the converse was not the case as ﬂavopiridol,
a CDK9 inhibitor, did not inhibit PKC. In summary,
some transcriptional effects of PKC inhibitors must be
reinterpreted in this new light.
Recent development in genome-wide analyses and bio-
informatics revealed that the elongation –step of transcrip-
tion plays a central role in the regulation of gene expression
(2–4). Particularly, P-TEFb plays a critical role in this
Figure 6. Activation of PKC via phorbol ester or the TCR releases HEXIM1 in Jurkat T cells, which is blocked by the DN PKCy protein. (A) PMA
and anti-CD3/anti-CD28 antibodies release phosphorylated HEXIM1 protein from 7SK snRNP. Jurkat T cells expressed the empty plasmid vector
(lanes 1–6) or DN-PKCy (lanes 7 and 8). Forty-eight hours after the transfection, cells were untreated (lanes 1 and 2), or treated with PMA (20 nM,
lanes 3 and 4), or anti-CD3/anti-CD28 antibodies (lanes 4 and 8) for 30min. High and low salt fractions were subjected to western blotting with
anti-HEXIM1 (upper panel, Hex) and anti-phosphoylated HEXIM1 (lower panel, (P)Hex) antibodies. Hex release was determined as in Figure 5A.
(B) The DN PKCy protein inhibits the release of CycT1 from the 7SK snRNP. Left panel: Glycerol gradient sedimentation was performed as above
(top panels, CycT1) and in the presence of DN-PKCy (bottom panel). CycT1 of each fraction was detected with anti-CycT1 antibodies by western
blotting. Whereas CycT1 in lanes 1–3 represents free P-TEFb, that in lanes 5–7 is in the 7SK snRNP. Right panel: Band intensities in fractions
corresponding to free P-TEFb and 7SK snRNP were quantiﬁed and the ratio between these two groups was calculated and plotted as a fold-increase
over the value obtained with unstimulated Jurkat cells.
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process. Thus, its function must be tightly controlled at
multiple steps, which include levels of expression of its
subunits and those of 7SK snRNP, their post-translational
modiﬁcations, the CDK9 kinase activity and the recruit-
ment of P-TEFb to target genes (17,23,61,62). In this
study, we elucidated a new mechanism by which cellular
signaling affects directly the integrity of the 7SK snRNP.
Further studies of 7SK snRNP, its assembly and disassem-
bly via discrete and convergent signaling pathways will
shed light onto this complex regulation that likely
controls the transcription of most cellular genes.
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